Afuresertib

Drug Profile

Afuresertib

Alternative Names: 2110183; Afuresertib hydrochloride; ASB183; GSK-2110183; GSK2110183B; GSK2110183C

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Novartis Oncology; University Health Network
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma; Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Jan 2017 Discontinued - Phase-I for Cancer (In volunteers) in Australia, Australia (PO) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-I for Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in South Korea, Taiwan (PO) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Taiwan, Ireland, Australia, Canada (PO) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top